{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:54:24Z","timestamp":1788173664565,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016879","name":"Union Chimique Belge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.molmed.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:13:45Z","timestamp":1752606825000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["10 years in lupus \u2013 progress, but not enough"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F.","family":"Morand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.06.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus","volume":"383","author":"Morand","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.molmed.2025.06.003_bb0010","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-209058","article-title":"Improved survival in rheumatoid arthritis: a general population-based cohort study","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","article-title":"Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999\u20132014)","volume":"57","author":"Jorge","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.molmed.2025.06.003_bb0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.06.003_bb0025","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0030","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0035","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/keab883","article-title":"Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index","volume":"61","author":"Carter","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.molmed.2025.06.003_bb0040","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/rheumatology\/keab777","article-title":"Measurement of specific organ domains in lupus randomised controlled trials: a scoping review","volume":"61","author":"Connelly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.molmed.2025.06.003_bb0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.06.003_bb0050","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.06.003_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0060","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrrheum.2014.118","article-title":"The need to define treatment goals for systemic lupus erythematosus","volume":"10","author":"Franklyn","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0070","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0075","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0080","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2665-9913(24)00121-8","article-title":"Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study","volume":"6","author":"Golder","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0085","doi-asserted-by":"crossref","first-page":"E822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13075-017-1256-6","article-title":"Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study","volume":"19","author":"Golder","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2025.06.003_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.molmed.2025.06.003_bb0100","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S2665-9913(19)30048-7","article-title":"Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000955","article-title":"Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort","volume":"5","author":"Ugarte-Gil","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.molmed.2025.06.003_bb0110","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/0961203319862614","article-title":"Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus","volume":"28","author":"Poomsalood","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2025.06.003_bb0115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0125","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/annrheumdis-2017-212504","article-title":"Lupus low disease activity state (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab","volume":"77","author":"Morand","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0135","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0140","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0145","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40265-024-02043-2","article-title":"Targeting interferon signalling in systemic lupus erythematosus: lessons learned","volume":"84","author":"Jones","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.molmed.2025.06.003_bb0150","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.coi.2012.10.004","article-title":"The pathogenesis of systemic lupus erythematosus-an update","volume":"24","author":"Choi","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0155","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1191\/096120300674499064","article-title":"Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2025.06.003_bb0160","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.06.003_bb0165","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0170","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0180","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.06.003_bb0185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri3850","article-title":"Aicardi\u2013Gouti\u00e8res syndrome and the type I interferonopathies","volume":"15","author":"Crow","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0190","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.06.003_bb0195","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41590-024-01846-5","article-title":"Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus","volume":"25","author":"Al-Azab","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0200","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/0961203320935976","article-title":"Characterization of type-I IFN subtype autoantibodies and activity in SLE serum and urine","volume":"29","author":"Harris","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2025.06.003_bb0205","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/art.39607","article-title":"Distinct functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0210","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2013 a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.06.003_bb0215","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA\u2013CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0220","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2025.06.003_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2025.06.003_bb0230","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-024-45056-x","article-title":"Smith-specific regulatory T cells halt the progression of lupus nephritis","volume":"15","author":"Eggenhuizen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.06.003_bb0235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2024-eular.2410","article-title":"Prevalence and outcomes of severe refractory systemic lupus erythematosus (SLE): observations from a multinational cohort","volume":"83","author":"Kandane-Rathnayake","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb2005","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.06.003_bb0245","article-title":"Safety and efficacy of subcutaneous Ianalumab (VAY736) for up to 68 weeks in patients with systemic lupus erythematosus: results from Phase 2 study","volume":"76","author":"Mysler","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0250","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.molmed.2025.06.003_bb0255","first-page":"L16","article-title":"Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: efficacy and safety results of a phase 3 trial","volume":"76","author":"Clowse","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0260","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0265","first-page":"12L","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomized, placebo-controlled, Phase IIb study","volume":"68","author":"Merrill","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0270","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.06.003_bb0275","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.06.003_bb0280","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.06.003_bb0285","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0290","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2022-eular.5020a","article-title":"Efficacy and safety of deucravacitinib, an oral, selective, allosteric Tyk2 inhibitor, in patients with active systemic lupus erythematosus: a Phase 2, randomized, double-blind, placebo-controlled study","volume":"81","author":"Morand","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0295","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","volume":"2","author":"Apostolopoulos","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0300","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0305","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-alpha quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0310","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2025.06.003_bb0315","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2665-9913(21)00006-0","article-title":"Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study","volume":"3","author":"Northcott","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0320","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/annrheumdis-2015-207744","article-title":"Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus","volume":"75","author":"Jones","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0325","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2015.05.010","article-title":"GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation","volume":"61","author":"Jones","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2025.06.003_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034880","article-title":"Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ)","volume":"13","author":"Dankers","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102858","article-title":"GILZ regulates type I interferon release and sequesters STAT1","volume":"131","author":"Nataraja","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2025.06.003_bb0340","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd4227","article-title":"Systemic lupus erythematosus and lupus nephritis","volume":"13","author":"Koutsokeras","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2025.06.003_bb0345","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","article-title":"Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2\/3 trials","volume":"81","author":"Bruce","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2025.06.003_bb0350","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.06.003_bb0355","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.06.003_bb0360","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/S2665-9913(21)00119-3","article-title":"Clinician-reported outcome measures in lupus trials: a problem worth solving","volume":"3","author":"Connelly","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0365","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","article-title":"Clinician-reported outcome assessments of treatment benefit \u2013 report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force","volume":"20","author":"Powers","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.molmed.2025.06.003_bb0370","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41584-023-00993-7","article-title":"Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce","volume":"19","author":"Connelly","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0375","author":"US Department of Health and Human Services"},{"key":"10.1016\/j.molmed.2025.06.003_bb0380","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.2023-0721","article-title":"Patient and physician perspectives of systemic lupus erythematosus flare: a qualitative study","volume":"51","author":"Rogers","year":"2023","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0385","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3899\/jrheum.2024-0122","article-title":"Flare in systemic lupus erythematosus: lost in translation?","volume":"51","author":"Morand","year":"2024","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2025.06.003_bb0390","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0961203317722412","article-title":"Discordance of patient and physician health status concerns in systemic lupus erythematosus","volume":"27","author":"Golder","year":"2018","journal-title":"Lupus"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:25:39Z","timestamp":1768407939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1471491425001431"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.06.003","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"10 years in lupus \u2013 progress, but not enough","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}